{
  "id": 1467097,
  "title": "Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis",
  "url": "https://urgent.news/2026/08/17/argenx-declares-phase-3-win-for-vyvgart-hytrulo-in-autoimmune-myositis",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-17T10:51:24.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/argenx-declares-phase-3-win-for-vyvgart-hytrulo-in-autoimmune-myositis/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Argenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drug",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}